Trial Profile
A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Udenafil (Primary)
- Indications Congenital heart defects; Ventricular dysfunction
- Focus Adverse reactions
- Acronyms FUELExten
- Sponsors Mezzion
- 21 Dec 2021 According to a Mezzion media release, new data from its Phase 3 efficacy and safety trial (FUEL Trial) and its open label extension trial (FUEL OLE Trial) was presented to the U.S. Food and Drug Administration (FDA) in a Type C meeting held on December 16, 2021.
- 22 Nov 2020 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.
- 08 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.